Diagnosis

Asthma

A chronic inflammatory disease of the airways characterized by recurrent reversible attacks of dyspnea and wheezing that either resolves spontaneously or responds to treatments.

Etiology

Cases for airway hyperreactivity

  1. Environmental allergens: animal allergens (cat and dog), fungi

  2. Viral respiratory tract infections

  3. Exercise/hyperventilation (cold/dry air or pollutants cause bronchoconstriction)

  4. Gastroesophageal reflux disease (increases airway resistance and reactivity)

  5. Chronic sinusitis or rhinitis

  6. Aspirin, NSAID or sulfite hypersensitivity

  7. Beta blockers

  8. Obesity

  9. Environmental pollutants, tobacco smoke

  10. Occupational exposure

  11. Irritants: household sprays, paint fumes, insects, plants, latex, gums, diisocyanates, anhydrides, wood dust, fluxes

  12. Emotional factors or stress

  13. Perinatal factors: prematurity, increased maternal age, maternal smoking

Pathophysiology

Epidemiology

Prevalence per 100.000 [rwn][mro][hdq]

Epidemiology chart for Prevalence

Incidence per 100.000 [rwn][mro][hdq]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Accessory muscles of respiration, Agitation, Bronchorrhea, Confusion, Cough, Cyanosis, Decreased consciousness, Decreased respiratory sounds, Diaphoresis, Dyspnea, Intercostal retraction, Nasal flaring, Somnolence, Tachycardia, Tachypnea, Wheezing

Clinical findings

Acidosis, Elevated IgE, Eosinophilia, Hypercarbia, Hypoxemia, Pulmonary hyperinflation, Pulsus paradoxus, Respiratory acidosis

Anamneses

None listed.

Localized findings

Pain
Radiates
Thorax
Onset
Acute (minutes)Subacute (hours)Gradual (days)
Pattern
ConstantIncreasing
Provoked by
Activity
Decreased by
RestSitting
Quality
CrampingPressing
Severity
Mild (1-3)Moderate (4-7)

Approach

Treatment

Treatment dependant on severity and frequency. Treatment goals are to reduce asthma-related symptoms and risk of future exacerbations.

Acute asthma exacerbation [osq][vkh]

  1. Oxygen mask

  2. Glucocorticoid inhaler (anti-inflammation)

  3. Beta-agonist inhaler (bronchodilation)

  4. Muscarinic antagonist inhaler

  5. Leukotriene modifier

  6. Systemic glucocorticoids (severe cases)

Profylaxis [osq][vkh]

  1. Environmental Control: identification and avoidance of asthma "triggers" (allergens, dust, cat, pollen, fumes, cigarette smoke)

  2. Immunotherapy: repeated injections of small doses of allergen (uncertain evidence)

  3. Monoclonal Antibody Therapy: Omalizumab / Mepolizumab / Reslizumab / Benralizumab / Dupilumab / Tezepelumab: decreases IgE antibody levels -> reduced histamine production/bronchospasm

  4. Bronchial Thermoplasty

Differential diagnoses

Acute sinusitis, Alpha1-antitrypsin deficiency, Anaphylaxis, Aspergillosis, Bronchiectasis, Bronchiolitis, Bronchitis, Bronchomalacia, Churg-Strauss syndrome, COPD, Croup, Cystic fibrosis, Foreign body, Gastroesophageal reflux disease, Heart failure, Pneumonia, Pulmonary embolism, Sarcoidosis, Tracheomalacia, Vocal cord immobility


References

[1] Torén et al. A prospective study of asthma incidence and its predictors: the RHINE study. Eur Respir J. 2004 Dec;24(6):942-6.

[2] Luo et al. Trends and age-period-cohort effects on incidence and mortality of asthma in Sichuan Province, China, 1990-2019. BMC Pulm Med. 2022 Aug 3;22(1):298.

[3] National Center for Health Statistics. (2023). 2022 NHIS Adult Summary Health Statistics. U.S. Department of Health and Human Services. https://data.cdc.gov/d/25m4-6qqq

[4] https://www.uptodate.com/contents/an-overview-of-asthma-management#H3

[5] http://emedicine.medscape.com/article/296301 (2014-02-03); [Medscape]

[6] https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm

[7] Lopez-Bago et al. Sex, Age, and Regional Disparities in the Burden of Asthma in Mexico from 1990 to 2019: A Secondary Analysis of the Global Burden of Disease Study 2019. Sustainability 2023, 15, 12599.

Scroll to top